Mark Bodmer - 07 May 2023 Form 4 Insider Report for Evelo Biosciences, Inc.

Role: CSO, President of R&D
Signature: /s/ Marella Thorell, Attorney-in-Fact for Mark Bodmer
Issuer symbol: EVLO on OTC
Transactions as of: 07 May 2023
Net transactions value: $0
Form type: 4
Filing time: 09 May 2023, 16:08:53 UTC
Previous filing: 09 Feb 2023
Next filing: 10 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EVLO	Common Stock	Options Exercise		+132,500	+60%		353,142	07 May 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EVLO	Restricted Stock Units	Options Exercise	$0	-132,500	-25%	$0.000000	397,500	07 May 2023	Common Stock	132,500		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
F2	The RSUs vest in four (4) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the first anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date. These RSUs have no expiration date.